Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 951 - 975 of 15727 in total
Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac. Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.
Approved
Investigational
Matched Description: … of Gallbladder, Biliary Tract and Pancrease. ... Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac ... Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Matched Iupac: … ethyl N-(2-amino-4-{[(4-fluorophenyl)methyl]amino}phenyl)carbamate …
Matched Description: … is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and
Flutemetamol (18F) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18. It is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Approved
Investigational
Matched Categories: … Indicators and Reagents …
Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells. It was...
Approved
Investigational
Matched Description: … cytokines and growth factors to promote tissue repair [A31818]. ... The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen ... (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells …
Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start...
Approved
Matched Description: … amount of poly and oligosaccharides in the diet. ... Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the ... glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and
Matched Categories: … Alimentary Tract and Metabolism …
Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver;...
Approved
Investigational
Matched Description: … [A263461] Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation. …
Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. Defects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red...
Approved
Investigational
Matched Description: … alpha- and beta-thalassemia. ... other hereditary red blood cell disorders associated with hemolytic anemia, such as sickle cell disease and
Matched Categories: … Blood and Blood Forming Organs ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.
Approved
Investigational
Matched Iupac: … methoxy-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]methyl
Matched Description: … An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. …
Matched Categories: … Ergot Alkaloids and Derivatives …
Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and...
Approved
Matched Iupac: … 13-chloro-2-{1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene}-4-azatricyclo[9.4.0.0^{3,8}]pentadeca …
Matched Description: … adult use and liquid formulation for pediatric use. ... Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is ... used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria …
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within...
Approved
Matched Description: … Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently ... through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and ... [F4645] It is also used off-label for the management of chorea associated with Huntington's disease and
Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. Elevated levels of eosinophils...
Approved
Investigational
Matched Description: … and promote programmed cell death [A31578]. ... , activation, and survival of eosinophils [FDA Label]. ... for recurrent exacerbation and asthma-related hospitalizations [A31579]. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Description: … vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and ... retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization ... many currently approved RVD therapies such as [aflibercept] and [ranibizumab] solely target VEGF-A. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Description: … stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and ... Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.
Approved
Matched Description: … Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and Bacillus aneurinolyticus . This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1,...
Approved
Matched Description: … Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus ... Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and ... other more minor contributors) and 40% neutral linear gramicidins (where valine-gramicidin A is often …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Approved
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,fenofibrate, and other conjugated compounds...
Approved
Matched Description: … for improved solubility, gastrointestinal absorption, and bioavailability, and more convenient administration ... acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and ... ], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed …
Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Iupac: … 1-(2-{[(4-chlorophenyl)methyl]sulfanyl}-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole …
Matched Description: … Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and ... [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial ... inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and
Matched Categories: … Imidazole and Triazole Derivatives …
Patent blue is aniline dye and it is one of the most common dyes used. It is a sodium or calcium salt of diethylammonium hydroxide inner salt. It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-2,5-cyclohexadiene-1-ylidene)diethylammonium hydroxide. Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979....
Approved
Matched Description: … Patent blue is aniline dye and it is one of the most common dyes used. ... Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979. …
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels. Cenobamate was granted FDA approval on 21 November 2019.
Approved
Investigational
Matched Description: … Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial ... of action has not been described in the literature, though it positively modulates GABAA and
Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
Approved
Investigational
Matched Description: … Antilipemic agent that lowers cholesterol and triglycerides. ... It decreases low density lipoproteins and increases high density lipoproteins. …
Matched Categories: … Benzamides and benzamide derivatives …
Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular Dystrophy (DMD). This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12. Often, patients succumb to this condition by age 30 or...
Approved
Matched Description: … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on ... Often, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Phloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing tablets. These tablets allow patients to visualise areas where more brushing and...
Approved
Matched Description: … These tablets allow patients to visualise areas where more brushing and flossing are needed. …
Matched Categories: … Indicators and Reagents …
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Matched Iupac: … 3-bromo-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2,6-dimethoxybenzamide …
Matched Categories: … Benzamides and benzamide derivatives …
Approved
Investigational
Nutraceutical
Displaying drugs 951 - 975 of 15727 in total